2Bonnet GL, Bonnet J. Mangment of acute myocardial infarction: What remains of intravenous thrombolysis[J]. Pre sse Med, 2011,40(6):611-614.
3Wilcox RG, Vonden LippeG, Olsson CG, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET)[J]. Lancet, 1988,2(8610):525-530.
4Gibson CM, Pride YB, Frederick PO, et al. Trends in reperfusion strategies,door-to-needle and door-to-balloon times, and in?hospital mortality among patients with ST -segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006[J]. Am Heart J, 2008, 156(6): 1035-1044.
5Nallamothu B, Fox KA, Kennelly BM, et al. GRACE Investigators Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention:the Global Registry of Acute Coronary Events[J]. Heart, 2007, 93(12):1552-1555.
6Lambert L, Brown K, Segal E, et al. Association between timeliness of reperfusion therapy and clinical outcomes in ST -elevation myocardial infarction[J]. JAMA, 2010, 303(21):2148-2155.
7Bonnefoy E, Steg PG, Boutitle F, et al. comparisonof primary angioplasty and pre-hospital olysis in acute myocardial infarc tion (CAPTIM) trial:a 5-year foliow-up[J].Eur Heart J, 2009, 30( 13): 1598-1606.
8Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients[J]. Lancet, 1994,5(343):311-322.
9Kumbhani OJ, Cannon CP, Fonarow GC. Association of hospital primary angioplasty volume in ST -segment elevation myocardial infarction with quality and outcomes[J]. JAMA, 2009, 302(20): 2007-2013.
10Kunadian V, Gibson CM. Thrombolytics and Myocardial infarction[J]. Cardiovasc Ther, 2012, 30(2):e81-88.
